Center For Advanced Magnetic Resonance Development (CAMRD)

Mission & Projects

The Center for Advanced Magnetic Resonance (MR) Development (CAMRD) is a research facility of the Department of Radiology at the Duke University Medical Center (DUMC). The Center’s mission is to support biomedical research within the Department, the Medical Center, and across the entire Duke research community. In addition to our own imaging technology-centered research, CAMRD faculty maintain active collaborations with research teams from the Duke Cancer Institute, Biomedical Engineering, the Pratt School of Engineering, and the Biomedical Research Imaging Center. We also support a large number of clinical trials as an imaging center and via core labs operated by our faculty.

The main resource of the center is a whole-body, commercially manufactured 3 Tesla (Trio, Siemens Healthcare) MR Imaging and Spectroscopy System with full research capabilities. It is housed in close proximity to the clinical MR systems of the Department of Radiology in the Duke North Hospital. We have a full complement of 1H receive coils as well as 19F, 31P, and 129Xe coils.

The Center is fully equipped to perform clinical and research MR imaging or spectroscopy studies on humans or large animals. A full range of monitoring, anesthesia, RF coil development, computer and instrumental control facilities as well as MR research technologists and physics/chemistry consultation are available to Department of Radiology researchers and their collaborators. We are also able to support research imaging of inpatients housed within the Duke University Hospital.

Submit a Project

CAMRD Approval Process:

  • CAMRD Review Committee meets once per month
  • Project needs to be submitted by the end of month prior to next scheduled meeting
  • Submit completed CAMRD Project Application, and a copy of your study consent to camrd-admins@dm.duke.edu. For your convenience: (Additional Information can be found here)
  • Funding source needs to be included (i.e. copy of grant application or fund code)
  • Review of project application does not require IRB approval; however, study activities in CAMRD will not begin until the IRB approval occurs
  • Projects with IRB and CAMRD committee approval can be scheduled by contacting Jean Shaffer by email: jean.shaffer@duke.edu or phone: 919.684.7400
  • Additional information on scheduling process and facility usage can be found here: CAMRD Guidelines

 Project Renewal:

Guidelines

Routine Guidelines for all human research studies conducted in CAMRD

  • The study team is responsible for scheduling subjects by contacting Jean Shaffer by email jean.shaffer@duke.edu or telephone 919.684.7400. At the time of scheduling, the CAMRD study number and subject ID are required.
  • All members of the study team are required to abide by CAMRD safety policies when accompanying subjects within the MRI department. Please see separate safety guidelines here: MRI Screening of Patients and Others.
  • Please ensure your subjects have completed the informed consent process prior to their arrival for their MRI exam.
  • Please ensure that any special subject preparation that is required for specific studies (i.e. fasting, NPO, IV placement, etc.) has been completed. Please note that the CAMRD team is unable to place IVs.
  • If an intravenous contrast agent is to be usedfemales of child-bearing potential must have a negative Pregnancy Test (serum beta-hCG) within 48 hours of the MRI exam. Test results will be verified by CAMRD personnel. For scans that do not use contrast agents, the IRB will allow a urine pregnancy test. This must be arranged ahead of time. CAMRD Contrast Use Guidelines.
  • A member of the study team must accompany the subject directly to CAMRD and stay for the duration of the imaging study. Please arrive at least 15 minutes prior to the scheduled appointment time.
  • The CAMRD Research Subject Information form and MRI Safety Screening form must be completed for each visit and presented to the technologist at the time of MRI appointment.
  • Documentation of any necessary lab values must be provided to the CAMRD MRI technologist before the MRI examination begins.
  • Please notify the CAMRD MRI technologist if the subject has an implanted device (i.e. stent, IUD, IVC filter) or has been injured by a metallic object (i.e. BB, bullet, shrapnel)– AT LEAST ONE WEEK PRIOR TO THE EXAMINATION DATE.
  • See additional information on CAMRD guidelines.
  • For animal projects, please contact us for further information.

Schedule

Scheduling Subjects:

  • To schedule subjects in CAMRD please review the calendar for availability and contact Jean Shaffer via email jean.shaffer@duke.edu or by telephone 919.684.7400. At the time of scheduling, the CAMRD study number and subject ID are required. (Note: For best view of the calendar time options, please view on a computer versus a mobile device (i.e. cell phone).
  • Also, at the time of scheduling, please review the Patient MRI Safety Screening form  with the subject to see if they have any implanted devices (i.e. stent, IUD, IVC filter) or have been injured by a metallic object (i.e. BB, bullet, shrapnel). Please notify CAMRD technologist AT LEAST ONE WEEK PRIOR TO THE EXAMINATION DATE of any implanted device or metallic object injury.
  • The CAMRD Research Subject Information form must be completed for each visit and presented to the technologist at the time of MRI appointment.
  • A member of the study team must accompany the subject directly to CAMRD and stay for the duration of the imaging study.
  • All labs, pregnancy tests, IV placements, consent for the study, the Research Subject Form, and MRI Safety Screening Form review must be completed prior to arriving for the scheduled appointment.
  • Please arrive at least 15 minutes prior to the scheduled appointment time to allow enough prep time for the subject and technologist.
  • If you are unable to arrive 15 minutes prior to the appointment time, please contact Jean Shaffer at 919.684.7400 as it may be necessary to reschedule
  • For additional CAMRD Guidelines, please click here

CAMRD Calendar

Contact

Leadership

Mustafa R. Bashir, MD – Medical Director
H. Cecil Charles, PhD – Scientific Director
Bastiaan Driehuys, PhD – Scientific Director

Faculty & Staff

Mustafa R. Bashir, MD
H. Cecil Charles, PhD
Bastiaan Dreihuys, PhD
Jennifer Korzekwinski, RT(N)CNMT – Protocol Submissions & Billing
Jean Shaffer, RT(R)MR – Lead Research Technologist
Brian Soher, PhD – Faculty

Scientific Committee

Mustafa R. Bashir, MD – Abdominal Imaging
H. Cecil Charles, PhD
Bastiaan Dreihuys, PhD
Joseph G. Mammarappallil, MD – Cardiothoracic Radiology
Rendon C. Nelson, MD, FACR – Abdominal Radiology
James M. Provenzale, MD, FACR – Neuroradiology
Brian Soher, PhD
Charles E. Spritzer, MD – Musculoskeletal Radiology

Mailing Address

Duke University Medical Center
Center for Advanced MR Development
2301 Erwin Road
Duke North, Room 1837
Durham, NC 27710

Phone: 919.684.7400
Email:    camrd-admins@dm.duke.edu

Research

Active Research Projects

 

CAMRD Project Number Principal Investigator Department Study Name
478 Dr. James Burke Neurology A Phase 2 Multiple Dose, Multicenter, Randomized,Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects
with Early Alzheimer’s Disease
477 Dr. Patrick Hickey Neurology A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects with Early Parkinson’s Disease
476 Dr. Krantz Radiology Estimation of ICP changes following treatment of spontaneous intracranial hypotension using MRI
475 Dr. Moorman Ortho Moximed ATLAS Knee Spring Study
474 Dr. Driehuys Radiology Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment
473 Dr. Driehuys Radiology Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis
472 Dr. Provenzale Radiology Measurements of Reproducibility of DTI Metrics on MR scanners using a DTI Phantom
471 Dr. Kishnani Pediatrics An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment with Velaglucerase alfa on Bone-related Pathology inTreatment-naïve Patients with Type 1 Gaucher Disease
470 Dr. Lisberger Neurobiology Neural Control of Eye Movement
469 Dr. Driehuys Radiology Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects with Pulmonary Disease
468 Dr.Manal Abdelmalek Gastroenterology A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects with Nonalcoholic Steatohepatitis
467 Dr.Manal Abdelmalek Medicine/GI A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis
465 Dr.Andrew Muir Gastroenterology A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED,PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATETHESAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR12 WEEKS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC)
464 Dr.Jing Cai Rad Onc Magnetic Resonance Imaging (MRI) solely FOR liver stereotactic body radiation therapy (SBRT)
463 Dr.Kevin Hill Pediatric Cardio CHD Brain Connectome Study
462 Dr.Manal Abdelmalek Gastroenterology A Phase 2 Double-Blind, Randomized, Placebo controlled,Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile AcidTransporter Inhibitor (ASBTi) in Adults withNonalcoholic Steatohepatitis (NASH
461 Dr.Lou De Frate Orthopedics Lumbar Spine – Pilot Study
460 Dr. Chino Rad Onc Rad Onc
459 Dr.Abdelmalek Medicine A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis.
458 Dr.Murat Rad Onc 63935937MYF2001 RESEARCH (Janssen Study)
457 Dr.Bridget Koontz Rad Onc abi rt prostate
456 Dr.Soher Radiology Characterization of 2HG Protocol for Monitoring IDH1+ Subjects Using Single-Voxel MR Spectroscopy
455  Lou DeFrate, MD Radiology In vivo measurement of patellar cartilage strain in response to running
454 Dr. Moylan-Bashir Medicine The Epigenetics of Pediatric Nonalcoholic Fatty Liver Disease and Fibrosis (SEEN:  Study of Early Life, Epigenetics and NAFLD)
453 Murat Arcasoy, MD Oncology A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
452 Dr. Priya Pediatrics-Medical Genetics Understanding cognitive and neurological pathologies in infantile Pompe disease
451 Grant E. Garrigues, MD Ortho Effect of exercise on glenohumeral cartilage mechanics
450 Dr. James Burke BrainTumor Clinic A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).
448 Dr. Katherine Peters BrainTumor Clinic A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Solid Tumors, Including Gliomas, with an IDH1 and/or IDH2 Mutation
446 Manal Abdelmalek Gastroenterology A Phase IIb, double blind randomized, controlled clinical trial, to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic Steatohepatitis (NASH
445 Burton Scott, MD Neurobiology A Phase 2, multi-center, randomized, double-blind, Placebo controlled study in subjects with late prodromal And early manifest Huntington disease (HD) to assess the safety, Tolerability, pharmacokinetics, and efficacy of VX15/2503
444 Dr. Kreissman Peds AALL1131 A Phase III Randomized Trial for Newly Diagnosed HR Pre-B ALL Testing Clofarbine
443 Jeffrey Crawford, MD                             Richard  Reidel, MD Oncology Alliance A091105: A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
442 Murat Arcasoy, MD Oncology GS-US-352-1214 Memolotinib
441 Manal Abdelmalek Gastroenterology A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH).
440 Manal Abdelmalek Gastroenterology A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults with Non-alcoholic Steatohepatitis
438 Richard Riedel, MD Oncology A Double-blind, randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath
437 Abdelmalek  Manal  MD Medicine /GI A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
435 Dr. Barboriak DCRU-BTC Phase I Single-Center, Dose Escalation Study of D2C7-IT Administered Intratumorally via Convection-Enhanced Delivery for Adult Patients with Recurrent Malignant Glioma
434 DR. Edward Smith Pediatric Neurology A phase 2 randomized, double-blind,placebo-controlled, multiple ascending dose study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of PF-06252616 in ambulatory boys with Duchenne Muscular Dystrophy,
431 Dr. Toth Orthopedics The Use of the Miniopen Approach to Address Massive Rotator Cuff Tears with Alternative Matrix Supplementation
430 Dr.Manal Abdelmalek Medicine IMM-124E-2001: A phase II randomized, double-blind, placebo-controlled, 3-arm parallel group, multi-dose, multi-center study of IMM-124E (bovine colostrum) for patients with non-alcoholic steatohepatitis (NASH).
428 William Garrett MD Orthopedics Verifying the Effectiveness of the NUsurface System
427 Michaeil Harrison MD Med Onc Duke Cancer :  EXTEND:  Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination with Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer
423 Claude Moorman, MD Ortho Prospective, Multi-Center, Pilot Study to Evaluate Symptom Relief in Patients with Medial Knee Osteoarthritis (OA) Treated with KineSpring Knee Implant for Load Reduction
420 Alison Weidner OBGYN DEMAND
413 Brian J. Soher, PhD/Manal Abdemalek, MD Radiology Impact of fructose on Metabolism, Energy Homeostatis and MR biomarkers in NAFLD
412 Priya Kishnani, MD Pediatrics-Medical Genetics  Natural history and biomarkers of disease in glycogen storage disease type III.
408 Joseph Mathew, MD Anesthesiology-Cardiac Division Blood Brain barrier Function After Cardiopulmonary Bypass
407 Joseph Mathew, MD Anesthesiology Hydroxychloroquine and Cognitive Function after Cardiopulmonary Bypass
406 Priya Kishnani, MD  Pediatrics-Medical Genetics Role of Whole Body MRI as a Non-Invasive Technique for Monitoring Disease Progression and Treatment Efficacy in Pompe disease
404 Lorel Del Mar Pena,MD.,Ph.D. Pediatrics-Medical Genetics An open-label, multicenter, multinational, ascending dose study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of repeated biweekly infusions of neoGAA in naïve and alglucosidase alfa treated late-onset Pompe disease patients
403 James Burke, MD DCRC TOMORROW Study (Takeda)
396 Charles E. spritzer, MD., Louis E. DeFrate, PhD Radiology/Orthopedics The effect of mechanical stress, proteoglycan and collagen digesting enzymes on porcine explants as measured with T1-rho and T2 mapping
395 Steven A. Olson,MD  Orthopedics Assessment of Biomarkers Associated with joint Injury and Subsequent Post-Traumatic Arthritis
392  Cecil Charles, PhD Radiology Human Lung Regional Ventilation Defect Severity measured by Fluorine-19 Gas MRI
389 Marc A. Sommer, PhD Biomedical Engineering Single Neuron Recording in Behaving Monkeys
379 Murat Arcasoy, MD Oncology An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L
376  Lou DeFrate, MD Orthopedics Effect of Exercise on Cartilage Strain
365 Daniel Barboriak, MD Radiology Feasibility and reproducibility of advanced MRI methods in high grade gliomas after anti-angiogenic treatment
312 Jennifer M. Groh, PhD Center for Cognitive Neuroscience Anatomical scanning of rhesus macaque brain
306 Michael Platt, PhD Neurobiology Cortical and Subcortical Mechanisms of Eye Movement Control


Click here to view Inactive/Closed Research Projects